Related Experiment Video
Updated: Jun 18, 2026
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Piggybacking toward Progress for CAR T-Cell Therapy in Prostate Cancer
Patrick C Lee1,2, Michael T Schweizer1,2, Rosa Nadal1,2
1Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington.
Summary
P-PSMA-101, a novel CAR-T therapy targeting PSMA, demonstrated clinical activity but modest responses in two patients. A safety switch effectively reduced severe toxicities, showing promise for managing side effects in cellular therapies.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Prostate-specific membrane antigen (PSMA) is a target for cancer therapy.
- Chimeric antigen receptor T (CAR-T) cell therapy offers a promising approach for cancer treatment.
- Stem cell memory T cells may enhance the persistence and efficacy of CAR-T therapies.
Purpose of the Study:
- To evaluate the safety and efficacy of P-PSMA-101, a novel CAR-T therapy enriched with stem cell memory T cells targeting PSMA.
- To assess the clinical activity and response rates in patients treated with P-PSMA-101.
- To determine the effectiveness of an integrated caspase-9 (iCasp9) safety switch in mitigating treatment-related toxicities.
Main Methods:
- P-PSMA-101 therapy administration to patients with PSMA-expressing cancers.
- Monitoring of clinical activity, including PSA50 response rates.
- Assessment of immune effector-related toxicities and the efficacy of the iCasp9 safety switch.
Main Results:
- P-PSMA-101 exhibited notable clinical activity in the treated patients.
- PSA50 responses were generally modest, indicating room for improvement in efficacy.
- Severe immune effector-related toxicities were observed but were largely mitigated by the iCasp9 safety switch.
Conclusions:
- P-PSMA-101 represents a first-in-class PSMA-targeting CAR-T therapy with demonstrated clinical activity.
- The iCasp9 safety switch proved effective in managing severe toxicities associated with this cellular therapy.
- Further investigation is warranted to optimize the efficacy of P-PSMA-101 for improved patient outcomes.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...